Overview

* Materialise Q3 revenue beats analyst expectations despite a 3.5% yr/yr decline

* Adjusted EBITDA for Q3 misses analyst estimates

* Materialise Medical segment revenue grows 10.3% yr/yr, setting a quarterly record

Outlook

* Materialise expects 2025 revenue between 265,000k EUR and 280,000k EUR

* Company maintains 2025 Adjusted EBIT guidance of 6,000k EUR to 10,000k EUR

* Materialise cites geopolitical volatility impacting business environment

Result Drivers

* MEDICAL SEGMENT GROWTH - Materialise Medical segment revenue increased 10.3% yr/yr, setting a quarterly record

* MANUFACTURING SEGMENT DECLINE - Materialise Manufacturing segment revenue decreased 17.1% yr/yr due to macro-economic headwinds

* COST CONTROL MEASURES - Company implemented targeted cost control measures to protect operational profitability

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat EUR EUR

Revenue 66.25 65.10

mln mln (2

Analysts

)

Q3 EPS EUR 0.03

Q3 Net EUR 1.84

Income mln

Q3 Miss EUR 8.42 EUR 10

Adjusted mln mln (1

EBITDA Analyst)

Q3 Gross EUR

Profit 37.65

mln

Q3 EUR 2.52

Operatin mln

g Income

Q3 EUR 2.40

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for Materialise NV ( MTLS ) is $8.50, about 30.1% above its October 27 closing price of $5.94

* The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 26 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)